Carfilzomib + Carboplatin + Etoposide
Phase 1/2Completed 0 watching 0 views this week⚡ Active
40
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Extensive-Stage Small-Cell Lung Cancer
Conditions
Extensive-Stage Small-Cell Lung Cancer
Trial Timeline
Nov 5, 2013 → May 4, 2017
NCT ID
NCT01987232About Carfilzomib + Carboplatin + Etoposide
Carfilzomib + Carboplatin + Etoposide is a phase 1/2 stage product being developed by Amgen for Extensive-Stage Small-Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01987232. Target conditions include Extensive-Stage Small-Cell Lung Cancer.
Hype Score Breakdown
Clinical
13
Activity
8
Company
9
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01987232 | Phase 1/2 | Completed |
Competing Products
20 competing products in Extensive-Stage Small-Cell Lung Cancer